A simple, CE-marked, whole blood test, providing long-term prognostic data that can guide clinical management in inflammatory bowel disease (Crohn’s disease and ulcerative colitis).
Available from January 2019 in the UK*.
PredictSURE IBD™ is the world’s first, truly validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). PredictSURE IBD™ is based upon 10 years of extensive research on gene expression profiling of CD8+ T cells. This whole blood-based biomarker test is a major step towards personalised medicine in IBD.
PredictSURE IBD™ is an easy-to-set-up biomarker test, combined with a sophisticated, proprietary algorithm. PredictSURE IBD™ will tell you the likely course of your patients’ IBD; differentiating between an aggressive or milder form of the disease. All you need is a small blood sample from your patients and an on-line PredictSURE IBD™ account for rapid, on-line reporting. With PredictSURE IBD™ you can take control of Crohn’s disease and ulcerative colitis treatment options.
*Launching in EU through 2019
Select the best treatment option for your patients with PredictSURE IBD™
🗸 Provides additional information to support treatment choices for your patients
🗸 Understand your patients’ long-term prognosis from the point of diagnosis
🗸 Patient tested once at time of diagnosis
🗸 Enables your patients to plan their lives based on knowledge of likely disease activity
Take control of Crohn’s and colitis treatment options
🗸 Easy to run, 17-gene qPCR molecular test
🗸 Test up to 4 patients
🗸 2.5ml blood sample
🗸 Sophisticated proprietary algorithm
🗸 Fast turnaround
🗸 Simple to understand, on-line reporting